Europe
Nabriva Therapeutics announced that the Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for Contepo (Fosfomycin) to treat complicated urinary tract infections (cUTI), including acute pyelonephritis.
The company announced a new target of achieving zero CO2 emissions from all operations and transport by 2030.
Athera Biotechnologies AB - Apr 30, 2019 10:00 CEST
Up to 6 patients to be enrolled in the second cohort, initial data expected in fourth quarter 2019
System Offers New Options for Improving Outcomes in Treating Stroke
Recipharm AB will publish its interim report for January-March 2019 on 3 May at 07:45 am CET.
Biom’up announced its full-year results for the year ending December 31, 2018, as approved by the Company’s Board of Directors on April 29, 2019, and provided an update on its operations.
Following the capital increase and listing on Nasdaq, cash and cash equivalents totaled €314.1 million as of March 31, 2019
NHS England will acquire hepatitis C drugs from the companies at competitive prices and work to identify patients around the country.
MorphoSys AG and I-Mab Biopharma announced that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
PRESS RELEASES